PCA
STML

Private Capital Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Private Capital Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-31,064
Closed -$387K – 116
2014
Q3 		$387K Sell
31,064
-157,636
-84% -$1.94M 0.13% 100
2014
Q2 		$2.77M Buy
188,700
+56,700
+43% +$869K 0.89% 54
2014
Q1 		$2.69M Buy
+132,000
New +$3.2M 1.02% 41

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Capital Advisors's STML Position: Q4 2014 in Review

Private Capital Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2014, closing a stake of 31,064 shares — an estimated $387K sold.

Private Capital Advisors first reported a position in STML in Q1 2014 and held it in 3 quarters. The position peaked at $2.77M in Q2 2014. 62 funds tracked by Wall St. Rank hold STML as of Q4 2014.

  • Private Capital Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Private Capital Advisors sold 31,064 Stemline Therapeutics, Inc. shares in Q4 2014, an estimated $387K.
  • Private Capital Advisors first reported a position in Stemline Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • Private Capital Advisors's Stemline Therapeutics, Inc. position peaked at $2.77M in Q2 2014.
  • 62 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2014.

Based on Private Capital Advisors's 13F filing for Q4 2014, filed 29 Jan 2015.